Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
المؤلفون المشاركون
Lee, Christine
Louie, Thomas J.
Weiss, Karl
Gerson, Marvin
Arnott, Wendy
Gorbach, Sherwood L.
Valiquette, L.
المصدر
Canadian Journal of Infectious Diseases and Medical Microbiology
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-05-24
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Background.
This analysis examined the efficacy of fidaxomicin versus vancomycin in 406 Canadian patients with Clostridium difficile infection (CDI), based on data from 2 randomized, clinical trials.
Methods.
Patients received fidaxomicin or vancomycin 1.
Patients were assessed for clinical response recurrence of infection and sustained clinical response for 28 days after treatment completion.
Patients at increased risk of recurrence were subjected to subgroup analyses.
Results.
Clinical response rates for fidaxomicin (90.0%) were noninferior to those with vancomycin (92.2%; 95% confidence interval for difference: −7.7, 3.5).
However, fidaxomicin-treated patients had lower recurrence (14.4% versus 28.0%, p = 0.001 ) and higher sustained clinical response (77.1% versus 66.3%, p = 0.016 ).
Compared with vancomycin, fidaxomicin was associated with lower recurrence rates in all subgroups, reaching statistical significance in patients with age ≥ 65 years (16.0% versus 30.9%, p = 0.026 ), concomitant antibiotic use (16.2% versus 38.7%, p = 0.036 ), and non-BI strains (11.8% versus 28.3%, p = 0.004 ).
Higher sustained clinical response rates were observed for fidaxomicin compared with vancomycin in all subgroups; this was statistically significant in the non-BI subgroup (82.8% versus 69.1%, p = 0.021 ).
Conclusions.
In Canadian patients, fidaxomicin was superior to vancomycin in sustaining clinical response and reducing CDI recurrence.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Lee, Christine& Louie, Thomas J.& Weiss, Karl& Valiquette, L.& Gerson, Marvin& Arnott, Wendy…[et al.]. 2016. Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology،Vol. 2016, no. 2016, pp.1-8.
https://search.emarefa.net/detail/BIM-1100012
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Lee, Christine…[et al.]. Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology No. 2016 (2016), pp.1-8.
https://search.emarefa.net/detail/BIM-1100012
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Lee, Christine& Louie, Thomas J.& Weiss, Karl& Valiquette, L.& Gerson, Marvin& Arnott, Wendy…[et al.]. Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology. 2016. Vol. 2016, no. 2016, pp.1-8.
https://search.emarefa.net/detail/BIM-1100012
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1100012
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر